Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

The Novavax vaccine targets the same XBB.1.5 variant as the other two vaccines. That variant was the dominant one in the U.S. earlier this year when the FDA had to choose the makeup of this fall's ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...

The FDA was on track to grant Novavax full approval by its April 1 target date, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss ...

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Most of the FDA’s Vaccines and Related Biological Products Advisory Committee voted “yes” in response to a question of whether the benefits of Novavax’s vaccine, given as a two-dose ...

Novavax recently struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) for its COVID vaccine, bolstering a company that had lost most of its value since the pandemic.

The US Food and Drug Administration on Wednesday authorized Novavax’s Covid-19 vaccine for emergency use in adults. It is the fourth coronavirus vaccine available in the United States, and it ...

The Novavax vaccine would be authorized for use in adults only in two doses. The company submitted a request, which the FDA is considering, to provide the same vaccine as a booster dose.

During the review on Tuesday, the FDA's advisers pushed Novavax representatives on multiple points. Signage outside the Novavax facility in Gaithersburg, Md., May 18, 2022.

U.S. regulators Wednesday authorized the nation’s fourth coronavirus vaccine, a shot developed by Novavax, a Maryland biotechnology company that has been a straggler in the vaccine race. How ...